Kyle C. McElyea

A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157

E. Plimack, A. Ross, G. Netto, 2016, Clinical Cancer Research.

Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer

T. Zimmers, P. Crooks, H. Nakshatri, 2017, Molecular Cancer Therapeutics.

Early-Stage Metastasis Requires Mdm2 and Not p53 Gain of Function

David J. Olivos, Eric R. Wolf, G. Sandusky, 2017, Molecular Cancer Research.

Dependence receptor UNC5A restricts luminal to basal breast cancer plasticity and metastasis

Xi Rao, Yunlong Liu, H. Nakshatri, 2018, Breast Cancer Research.

Applying Small Molecule Signal Transducer and Activator of Transcription-3 (STAT3) Protein Inhibitors as Pancreatic Cancer Therapeutics

K. Kerman, P. Lai, G. Sandusky, 2016, Molecular Cancer Therapeutics.

Critical role of phosphorylation of serine 165 of YBX1 on the activation of NF-κB in colon cancer

Yunlong Liu, G. Sandusky, Antja-Voy Hartley, 2015, Oncotarget.

Dependence receptor UNC5A restricts luminal to basal breast cancer plasticity and metastasis

Yunlong Liu, H. Nakshatri, S. Perkins, 2018, Breast Cancer Research.